NCT06456138 - Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2028

Conditions

KRAS Mutation-Related TumorsAdvanced Lung CancerRefractory Tumor

Interventions

DRUG

Trametinib

Trametinib will be administrated orally every day.

DRUG

Anlotinib

Anlotinib will be administrated orally from day 1 to day 14 per 21-day cycle.

DRUG

Tislelizumab

Tislelizumab will be administered at full dose (200mg, Q3W) on the patient who received the efficacy evaluation of stable disease (SD) or partial response (PR) or complete response (CR) after 2 cycles' treatment of trametinib plus anlotinib.

Trial Locations (1)

Unknown

Shanghai Chest Hospital, Shanghai